Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ SET Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA141322
Description
The immunogen sequence is 100% identical in mouse and rat. Suggested positive control: Jurkat whole cell lysate.
SET is a multitasking protein, involved in apoptosis, transcription, nucleosome assembly and histone binding. Isoform 2 anti-apoptotic activity is mediated by inhibition of the GZMA-activated DNase, NME1.
Specifications
SET | |
Polyclonal | |
Unconjugated | |
SET | |
2610030F17Rik; 2PP2A; 5730420M11Rik; AA407739; Ab1-115; HLA-DR-associated protein II; hypothetical protein LOC538444; I IGAAD; I2PP2A; I-2PP2A; IGAAD; inhibitor of granzyme A-activated DNase; inhibitor-2 of protein phosphatase-2A; IPP2A2; Liver regeneration-related protein LRRGR00002; OTTHUMP00000022286; PHAPII; Phosphatase 2A inhibitor I2PP2A; protein phosphatase 2A inhibitor 2; protein phosphatase type 2A inhibitor; protein SET; RP11-216B9.3; Set; SET nuclear oncogene; SET nuclear proto-oncogene; SET translocation; SET translocation (myeloid leukemia-associated); SET-like protein; StF-IT-1; TAF-1a; TAF-1b; TAF-I; TAF-IBETA; Template-activating factor I; Template-Activating Factor-I, chromatin remodelling factor | |
Rabbit | |
Protein G | |
RUO | |
307947, 56086, 6418 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Western Blot, Immunocytochemistry | |
0.5 mg/mL | |
PBS with 100 μg/mL BSA and 0.02% sodium azide | |
Q01105, Q63945, Q9EQU5 | |
SET | |
Synthetic peptides corresponding to residues 66-81 and 135-151 of human INHAT-1. | |
100 μg | |
Primary | |
Human, Mouse, Rat | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction